NFKB1 and chronic obstructive pulmonary disease: In patients with COPD, regulation of NF-κB signaling activity is one of the essential therapeutic criteria, so the therapeutic use of corticosteroids inhibits NF-κB activity and consequently reduces the levels of inflammatory cytokines.